



2009 EMEA/IFAH-Europe Info Day

'THE LATEST DEVELOPMENTS' IN SCIENTIFIC REVIEW, LEGISLATION AND MARKETING AUTHORISATION PROCEDURES

12-13 March 2009, EMEA, London

Programme

Thursday 12th March 2008			
13:30	Registration open		
14:00	Introduction and Welcome	David Mackay, EMEA	
Session I:	Scientific Developments Cha	air: Kornelia Grein, EMEA	
14:10	An analysis of the changes to Annex 1 and their impact	Ray Harding, Cyton confirmed	
14:40	An analysis of the changes to Annex 1 and their impact: CVMP perspective	CVMP	
15:10	Discussion		
15:30	Review of main conclusions from recent scientific discussions:		
	 Oncology guideline for cats and dogs 	CVMP	
	PK/PD modelling	CVMP	
15:55	Tea and Coffee		
16:15	Biologicals - Developments in scientific requirements and procedures	IWP Chair person	
16:40	ERA Requirements - Clarification of requirements and procedures	ERA WP Chair or Vice Chair	
17:05	Discussion		
17:25	VICH : an update on developments following the 22 nd Steering Committee meeting in February 2009	Kornelia Grein, EMEA	
17:45	Close of the session by the chairman		
18:00	Cocktail reception, followed by supper at 18:30, EMEA canteen		





Friday 13 th March 2008			
Session II:	EMEA Bulletin board and procedures	Chair: David Mackay, EMEA	
09:00	Review of priorities for CVMP and its working parties for 2009 including plans for interactions with stakeholders	, CVMP Chairperson	
09:30	 Update on the Centralised Procedure Renewals and sunset clause: practical tips for compliance E-presentations 	Melanie Leivers, EMEA	
09:45	Survey of the centralized procedure	Sylvie Meillerais, IFAH- Europe	
	Industry perspectiveEMEA perspective	EMEA	
10:10	MRL Regulation – where we are now	EU Commission or EMEA Secretariat	
10:30	Tea and coffee		
Session III:	Legislation Developments <u>Chair</u> : Declan O'Brien, IFAH-Europe		
10:50	 Variations Regulation Are we on the right track Implementation proposal for the variation Regulation 	IFAH-Europe Variations Task Force Melanie Leivers, EMEA	
11:20	Discussion	,	
11:30	 Pharmacovigilance: how should the current challenge be met? Update on Volume 9B Detailed description of pharmacovigilance Streamlining PSURs 	CVMP Pharmacovigilance Working Party	
11:50	Pharmacovigilance : industry perspective on how the veterinary chapter should be reviewed	IFAH-Europe Pharmacovigilance Working Group	
12:10	Questions		
12:20	The 2010 Review: IFAH-Europe proposals for optimising veterinary medicines legislation	g Rick Clayton, IFAH- Europe	
12:40	Questions		
12:50	Close of the meeting	Declan O'Brien and David Mackay	